04/21/2026
We are pleased to share that our Phase 1 ABACUS-1 study of KIO-301 has been published in Nature Medicine. We are grateful for the opportunity to contribute to the peer-reviewed literature in this field.
As noted by Dr. Robert Casson, Principal Investigator of the study from the Royal Adelaide Hospital, the open-label, first-in-human trial met its primary safety endpoint, demonstrating short-term ocular safety and feasibility following intravitreal delivery, with no serious adverse events or dose-limiting toxicities reported. Exploratory findings — including light-induced cortical activity on fMRI and temporal improvements in functional vision measures in some participants — provide early clinical support for our molecular photoswitch approach.
We are deeply thankful to the patients and families who participated in the study, as well as the investigators, site teams, and our partners who made this milestone possible.
Read more at https://ir.kiorapharma.com/news-events/news-releases/detail/248/kioras-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway
